3 terminated, 2 active not recruiting, 2 completed, 2 recruiting. 12 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Terminated 3, Active not recruiting 2, Completed 2, Recruiting 2, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow taxane: new trials by email Literature Review of taxane trials Research Report on taxane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin - Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer | Phase 3 | Recruiting | Genelux Corporation | 186 | 2022-08-31 | 2026-08-26 |
| Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer Taxane plus Intermittent Capecitabine, Utidelone plus Intermittent Capecitabine, Taxane plus Metronomic Capecitabine - Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer | Phase 3 | Not yet recruiting | Sun Yat-sen University | 512 | 2022-03-01 | 2021-12-29 |
| Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) Trastuzumab deruxtecan, Placebo, Taxane - Breast Cancer; HER2-positive; Metastatic | Phase 3 | Active not recruiting | AstraZeneca | 1157 | 2021-04-26 | 2026-10-22 |
| NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC epirubicin, cyclophosphamide, paclitaxel, carboplatin, pembrolizumab, epirubicin, cyclophosphamide, capecitabine, paclitaxel, carboplatin, pembrolizumab - Breast Cancer, Triple Negative Breast Neoplasms | Phase 3 | Active not recruiting | Lund University Hospital | 325 | 2019-12-20 | 2025-09-12 |
| Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer Bavituximab, Taxane - Metastatic Breast Cancer | Phase 2 / Phase 3 | Withdrawn | Peregrine Pharmaceuticals | 2015-12-01 | 2017-07-11 | |
| Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial) taxane plus carboplatin, Taxane - Breast Cancer | Phase 3 | Unknown | Yonsei University | 878 | 2015-09-01 | 2024-06-04 |
| A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Taxane, trastuzumab emtansine - Gastric Cancer | Phase 2 / Phase 3 | Terminated | Hoffmann-La Roche | 415 | 2012-09-03 | 2017-05-12 |
| A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer Taxane, Avastin, Taxane, Avastin, Xeloda - Breast Cancer | Phase 3 | Terminated | GBG Forschungs GmbH | 432 | 2009-07-01 | 2013-05-22 |
| Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse Farletuzumab, Carboplatin, Taxane - Ovarian Cancer | Phase 3 | Terminated | Morphotek | 1100 | 2009-04-16 | 2022-12-30 |
| Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Paclitaxel (Taxane), Docetaxel (Taxane), Carboplatin - Non-Small-Cell Lung Carcinoma | Phase 3 | Completed | Eli Lilly and Company | 755 | 2004-12-01 | 2015-12-24 |
| A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes paclitaxel, docetaxel, taxane, taxane - Supportive, Ill-defined Sites | Phase 3 | Completed | New Mexico Cancer Research Alliance | 200 | 2002-06-01 | 2011-09-27 |
Breast Neoplasms (6) · Ovarian Neoplasms (2) · Breast Diseases (1) · Carcinoma, Non-Small-Cell Lung (1) · Fallopian Tube Neoplasms (1) · Neoplasm Metastasis (1) · Pathologic Complete Response (1) · Stomach Neoplasms (1) · Triple Negative Breast Neoplasms (1) · Vaccinia (1)
AstraZeneca (1) · Eli Lilly and Company (1) · GBG Forschungs GmbH (1) · Genelux Corporation (1) · Hoffmann-La Roche (1) · Lund University Hospital (1) · Morphotek (1) · New Mexico Cancer Research Alliance (1) · Peregrine Pharmaceuticals (1) · SWOG Cancer Research Network (1) · Sun Yat-sen University (1) · Yonsei University (1)
United States (8) · Germany (4) · South Korea (4) · Argentina (3) · Belgium (3) · Brazil (3) · Canada (3) · China (3) · France (3) · Hungary (3) · Italy (3) · Japan (3) · Mexico (3) · Philippines (3) · Russia (3)
Ian Rabinowitz, MD (1) · Kathy Miller, MD (1) · Mariya Rozenblit (1) · Niklas Loman, MD, PhD (1) · Robert W. Holloway, MD (1)
PMID 28343975, PMID 30706247, PMID 34686353, PMID 37166557, PMID 37227734, PMID 37666539, PMID 41160818
2008 (2), 2015 (1), 2023 (1), U10CA180888 (1)